167 related articles for article (PubMed ID: 18072254)
1. Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Come SE; Buzdar AU; Ingle JN; Johnston SRD; Brodie AM; Coombes RC; Miller WR; Pritchard KI; Winer EP; Zujewski JA; Goss PE
Cancer; 2008 Feb; 112(3 Suppl):673-678. PubMed ID: 18072254
[TBL] [Abstract][Full Text] [Related]
2. [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Thürlimann B; Senn HJ
Gynakol Geburtshilfliche Rundsch; 2005 Jun; 45(3):143-6. PubMed ID: 15990439
[TBL] [Abstract][Full Text] [Related]
3. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
5. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
6. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
7. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
8. Anastrozole data show continued delay in relapse, but no clear survival advantage.
Travis K
J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
[No Abstract] [Full Text] [Related]
9. Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A; Gil M; Sánchez-Rovira P; Llombart A; Adrover E; Estevez LG; de la Haba J; Calvo L
Anticancer Drugs; 2008 Apr; 19(4):339-47. PubMed ID: 18454044
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors--a triumph of translational oncology.
Swain SM
N Engl J Med; 2005 Dec; 353(26):2807-9. PubMed ID: 16382068
[No Abstract] [Full Text] [Related]
11. Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
O'Leary CG; Ellis H; Higgins M
Curr Opin Oncol; 2016 Nov; 28(6):455-460. PubMed ID: 27606696
[TBL] [Abstract][Full Text] [Related]
12. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Glück S
Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
[TBL] [Abstract][Full Text] [Related]
13. [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].
Longo F; Mansueto G
Tumori; 2004; 90(6):1-12. PubMed ID: 15762372
[No Abstract] [Full Text] [Related]
14. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
[TBL] [Abstract][Full Text] [Related]
15. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Kahán Z
Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
[No Abstract] [Full Text] [Related]
16. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Baum M
Eur J Cancer; 2005 Aug; 41(12):1667-77. PubMed ID: 16046117
[TBL] [Abstract][Full Text] [Related]
17. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
18. Update of the BIG 1-98 Trial: where do we stand?
Joerger M; Thürlimann B
Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Buzdar AU; Cuzick J
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
